Clinical Research Directory
Browse clinical research sites, groups, and studies.
Intensive Cancer Screening After Cryptogenic Stroke
Sponsor: Ottawa Hospital Research Institute
Summary
The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.
Official title: Intensive Cancer Screening After Cryptogenic Stroke (INCOGNITO) Pilot Randomized Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2023-09-01
Completion Date
2028-01
Last Updated
2026-10-15
Healthy Volunteers
No
Conditions
Interventions
FDG PET/CT
F-fluorodeoxyglucose positron emission/computed tomography
Usual Care
Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care
Locations (3)
Calgary Foothills Medical Centre
Calgary, Alberta, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada